This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

PTC Therapeutics Expands Management Team

SOUTH PLAINFIELD, N.J., Jan. 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced an expansion of its senior management team with the appointment of Robert J. Spiegel M.D., FACP to Chief Medical Officer and Murad Husain to Vice President, Global Regulatory Affairs. PTC also announced the promotions of Joseph Colacino, Ph.D. to Senior Vice President, Drug Discovery and Ernest R. Dietel to Senior Vice President, Quality. In addition, Jay Barth, M.D., Senior Vice President of Clinical Development, is leaving PTC to pursue other opportunities.

(Logo:   http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

In 2011, Dr. Spiegel joined PTC on a part-time consulting basis as Chief Medical Officer. In his new role, he will be responsible for all aspects of clinical development. Prior to joining PTC, Dr. Spiegel was Chief Medical Officer of Schering-Plough and was involved in the filing of New Drug Applications and interacting with regulatory authorities in the U.S. and globally on a regular basis. He also served on the executive committees overseeing research projects and drug licensing activities. Dr. Spiegel joined Schering-Plough in 1983 as Director, Clinical Research, progressing through clinical operations as Vice President of Clinical Research, Senior Vice President of Worldwide Clinical Research and then becoming Chief Medical Officer in 1998. He received his undergraduate degree, cum laude, from Yale University and his medical degree from the University of Pennsylvania. He is currently an Associate Professor at Weill Cornell Medical Center and serves on the Board of Directors and Scientific Advisory Committees of a number of companies. 

In his role as Vice President of Global Regulatory Affairs, Mr. Husain will lead the regulatory efforts to support PTC's lead product candidate, ataluren, and other clinical programs. He brings to PTC more than 25 years of pharmaceutical industry experience, with 20 years in regulatory affairs. Prior to PTC, Mr. Husain was Vice President, Regulatory Affairs at Savient Pharmaceuticals, Inc. He has led numerous worldwide regulatory teams for drug and biologics development and registration while at Pfizer, Hoffman-La Roche, Serono, AstraZeneca and Forest Laboratories. He achieved approvals of original NDAs, BLAs and new indications for drugs and biologics in pulmonary, oncology, CNS, rheumatology and anti-infective therapeutic areas. He received his M.S. in Pharmaceutical Marketing from St. John's University and his Masters and Bachelors in Pharmacology from the University of Dhaka.

Joseph M. Colacino, Ph.D. joined PTC in March 2003 as Vice President of Drug Discovery. Dr. Colacino oversees drug discovery activities across therapeutic areas including genetic disorders, oncology, and infectious diseases programs. He has actively participated in PTC's business development and grant efforts from government and other funding agencies, has served on steering committees for a number of our collaborations, and has been the principal investigator on a number of scientific grants. Dr. Colacino joined PTC after 14 years at Eli Lilly and Company, where he held positions as Research Acquisition Advisor, Director of Virology, and Head of Biology for Infectious Diseases Research. Dr. Colacino has served on special emphasis panels for the review of grant applications in oncology and virology. He is widely published and serves on the editorial board of Antimicrobial Agents and Chemotherapy and is an expert reviewer for Journal of Virology, Virology, Virology Research, Antiviral Research, Journal of Medicinal Chemistry, and Proceedings of the National Academy of Science. From 2010-2012, he was the president of the International Society for Antiviral Research and is currently past president of the Society. Dr. Colacino received his Ph.D. in Virology from the Cornell Graduate School of Medical Sciences, New York City.

As Senior Vice President of Quality, Mr. Ernest Dietel is responsible for GxP quality management operations at PTC. He joined the company in 2009 and became Vice President of Quality Assurance in 2012. From 2005 to 2009, he served as President of DRE Enterprises, Inc., a consulting company that provided services to the pharmaceutical industry in areas of quality, manufacturing, validation, regulatory and business development. Prior to DRE Enterprises, he held various roles in Quality and Manufacturing at Pliva, Inc. and Hoffmann-La Roche, Inc. Mr. Dietel holds an MBA in management from Farleigh Dickinson University and a BA in Chemistry from Bloomfield College.

"We are excited that Dr. Spiegel will expand his role at PTC. His expertise has been valuable in the development of ataluren and our other clinical programs," stated Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. "I would like to welcome Mr. Husain to our senior management team. Mr. Husain's global regulatory experience will be a valuable contribution to the company. In addition, I am proud to announce the promotions of Dr. Colacino and Mr. Dietel. They have served important roles in our drug discovery and our quality assurance functions. These important additions to our management team will enable PTC to advance our clinical and research programs consistently with our goal of becoming a global fully integrated discovery, development and commercial company."

About PTC Therapeutics, Inc.

PTC is biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and which form the basis for collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com.

PTC THERAPEUTICS, INC. FORWARD LOOKING STATEMENTS:

Any statements in this press release about future expectations, plans and prospects for PTC, the development of and potential market for PTC's product candidates, our clinical trials, our current and planned regulatory submissions, our earlier stage programs, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" in the most recent Quarterly Report, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent PTC's views only as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's views as of any date subsequent to the date of this press release.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs